UBT251 Injection advances to Phase III, targeting Semaglutide non-inferiority in Type 2 Diabetes.
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
Abstract
UBT251 Injection begins Phase III trial to assess non-inferiority against Semaglutide for glycemic control in Type 2 Diabetes patients.